Gammanorm 165 mg/ml inj. sol. i.m./s.c. vial Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

gammanorm 165 mg/ml inj. sol. i.m./s.c. vial

octapharma benelux sa-nv - human normal immunoglobulin 165 mg/ml - solution for injection - 165 mg/ml - human normal immunoglobulin 165 mg/ml - immunoglobulins, normal human, for extravascular adm.

Gammanorm 165 mg/ml inj. sol. i.m./s.c. vial Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

gammanorm 165 mg/ml inj. sol. i.m./s.c. vial

octapharma benelux sa-nv - human normal immunoglobulin 165 mg/ml - solution for injection - 165 mg/ml - human normal immunoglobulin 165 mg/ml - immunoglobulins, normal human, for extravascular adm.

Gammanorm 165 mg/ml inj. sol. i.m./s.c. vial Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

gammanorm 165 mg/ml inj. sol. i.m./s.c. vial

octapharma benelux sa-nv - human normal immunoglobulin 165 mg/ml - solution for injection - 165 mg/ml - human normal immunoglobulin 165 mg/ml - immunoglobulins, normal human, for extravascular adm.

Gammanorm 165 mg/ml inj. sol. i.m./s.c. vial Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

gammanorm 165 mg/ml inj. sol. i.m./s.c. vial

octapharma benelux sa-nv - human normal immunoglobulin 165 mg/ml - solution for injection - 165 mg/ml - human normal immunoglobulin 165 mg/ml - immunoglobulins, normal human, for extravascular adm.

Gammanorm 165 mg/ml inj. sol. i.m./s.c. vial Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

gammanorm 165 mg/ml inj. sol. i.m./s.c. vial

octapharma benelux sa-nv - human normal immunoglobulin 165 mg/ml - solution for injection - 165 mg/ml - human normal immunoglobulin 165 mg/ml - immunoglobulins, normal human, for extravascular adm.

Gammanorm 165 mg/ml inj. sol. i.m./s.c. vial Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

gammanorm 165 mg/ml inj. sol. i.m./s.c. vial

octapharma benelux sa-nv - human normal immunoglobulin 165 mg/ml - solution for injection - 165 mg/ml - human normal immunoglobulin 165 mg/ml - immunoglobulins, normal human, for extravascular adm.

Gammanorm New Zealand - English - Medsafe (Medicines Safety Authority)

gammanorm

octapharma new zealand ltd - normal immunoglobulin 165 mg/ml - solution for injection - 165 mg/ml - active: normal immunoglobulin 165 mg/ml excipient: glycine immunoglobulin a polysorbate 80 sodium tributyl phosphate water for injection - · replacement therapy in adults and children with primary immunodeficiency syndromes such as: - congenital agammaglobulinaemia and hypogammaglobulinaemia - common variable immunodeficiency - severe combined immunodeficiencies - igg subclass deficiencies with recurrent infections · replacement therapy in myeloma or chronic lymphatic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections.

GAMMANORM 165 Mg/Ml Solution for Injection Ireland - English - HPRA (Health Products Regulatory Authority)

gammanorm 165 mg/ml solution for injection

octapharma limited - immunoglobulin g - solution for injection - 165 mg/ml

Gammanorm 3.3g/20ml solution for injection vials United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

gammanorm 3.3g/20ml solution for injection vials

octapharma ltd - normal immunoglobulin human - solution for injection - 165mg/1ml

GAMMANORM normal immunoglobulin (human) 3300mg/20mL solution for intramuscular injection or subcutaneous infusion vial Australia - English - Department of Health (Therapeutic Goods Administration)

gammanorm normal immunoglobulin (human) 3300mg/20ml solution for intramuscular injection or subcutaneous infusion vial

octapharma australia pty ltd - normal immunoglobulin, quantity: 3300 mg - injection, solution - excipient ingredients: tributyl phosphate; sodium chloride; water for injections; human immunoglobulin a; glycine; polysorbate 80; sodium acetate - replacement therapy in adults and children in primary immunodeficiency syndromes such as: congenital agammaglobulinaemia and hypogammaglobulinaemia, common variable immunodeficiency (cvid), severe combined immunodeficiencies, igg subclass deficiencies with recurrent infections. replacement therapy in myeloma or chronic lymphatic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections.